A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

被引：0
|
作者：
Meng, Xiangrui [1 ]
Shan, Zhengzheng [1 ]
Guan, Lulu [1 ]
Dao, Xin [1 ]
Fan, Qingxia [1 ]
Wang, Feng [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-5651-9270-10662; 298-145-222-184-1022-9124; 261-566-9718-9794; 130-540-543-4790; 261-492-2769; 3282-3306-2666-6279; 3282-3306-4614-3827; 3; 2; 2461; 3216; 1704; 239; 6; 1; 38092-34311; 38092-21759; 38116-38094-8; 38092-20072;
D O I：
10.1200/JCO.2024.42.3_suppl.335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：335 / 335
页数：1
相关论文
共 50 条
  • [1] Updated results from the phase Ib/II study of fruquintinib combined with SOX and toripalimab in patients with advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
    Shan, Zhengzheng
    Guan, Lulu
    Dao, Xin
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [2] A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results.
    Jin, Min
    Yang, Shengli
    Liu, Junli
    Zhang, Jieying
    Zhao, Lei
    Yu, Dandan
    Lin, Zhenyu
    Li, Pindong
    Wang, Jing
    Xue, Jun
    Ma, Hong
    Hu, Jianli
    Zhang, Tao
    Liu, Hongli
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 407 - 407
  • [3] Phase II study of cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Pinto, C.
    Di Fabio, F.
    Barone, C.
    Siena, S.
    Falcone, A.
    Cascinu, S.
    Rojas, Llimpe F.
    Artale, S.
    Schinzari, G.
    Giaquinta, S.
    Mutri, V
    Martoni, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 9 - 9
  • [4] Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.
    Jin, Min
    Yang, Shengli
    Liu, Junli
    Zhang, Jieying
    Zhao, Lei
    Yu, Dandan
    Lin, Zhenyu
    Li, Pindong
    Wang, Jing
    Xue, Jun
    Ma, Hong
    Hu, Jianli
    Zhang, Tao
    Liu, Hongli
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 332 - 332
  • [5] Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).
    Xu, Nong
    Shen, Lin
    Jiang, Haiping
    Zheng, Yulong
    Qian, Jiong
    Mao, Chenyu
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)
    Teng, L.
    Xu, N.
    Jiang, H.
    Zheng, Y.
    Qian, J.
    Mao, C.
    Zhou, H.
    Wang, S.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1759 - 1760
  • [7] Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study)
    Pinto, C.
    Di Fabio, F.
    Barone, C.
    Siena, S.
    Falcone, A.
    Llimpe, F. L. Rojas
    Cascinu, S.
    Giaquinta, S.
    Schinzari, G.
    Mutri, V.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Cetuximab in combination with folfiri as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results of folcetux phase II study
    Di Fabio, Francesca
    Pinto, Carmine
    Siena, Salvatore
    Cascinu, Stefano
    Ceccarelli, Claudio
    Llimpe, Fabiola Lorena Rojas
    Mutri, Vita
    Giaquinta, Stefania
    Piana, Edera
    Martoni, Andrea Angelo
    ANNALS OF ONCOLOGY, 2006, 17 : 309 - 310
  • [9] Phase II study of cetuximab in combination with folfiri as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results (FOLCETUX study)
    Pinto, C.
    Di Fabio, F.
    Siena, S.
    Cascinu, S.
    Rojas Llimpe, F. L.
    Ceccarelli, C.
    Mutri, V
    Giaquinta, S.
    Piana, E.
    Martoni, A. A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI54 - XI55
  • [10] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
12345